Company news

Vor Biopharma Inc. news in 2024

Vor Biopharma Inc.'s news releases, calls and decks from 2024, newest first.

View company

Vor Bio Announces $55.6 Million Private Placement

December 26, 2024

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

December 8, 2024

Vor Bio to Participate in the Stifel 2024 Healthcare Conference

November 11, 2024

Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update

November 6, 2024

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

September 29, 2024

New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies

September 4, 2024

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

August 7, 2024

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

May 8, 2024

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

May 1, 2024

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

March 19, 2024

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 6, 2024

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

January 16, 2024

Decks in 2024